Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric derisomaltose versus no intravenous iron in iron-deficient symptomatic chronic heart failure
2024-519059-28-00Phase 3Authorised
- Sponsor
- Pharmacosmos
- Start
- Jul 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in chronic heart failure (CHF) and iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Number of cardiovascular deaths and hospitalizations for worsening heart failure. Planned start Jul 2025; status: authorised.
02
Drugs
ferric derisomaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2024-519059-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519059-28-00.